The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
Abstract
Objective: To compare the efficacy, safety, and tolerability of 4 doses of oral tofacitinib (CP‐690,550) with placebo in Japanese patients with active rheumatoid arthritis (RA) receiving stable background methotrexate (MTX) who had an inadequate response to MTX alone. Methods: A total of 140 patients were randomized to receive tofacitinib 1, 3, 5, and 10 mg twice a day or placebo in this 12‐week, phase II, double‐blind study. All patients remained on background MTX. Efficacy and safety were assessed at weeks 1, 2, 4, 8, and 12. The primary efficacy end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Results: ACR20 response rates at week 12 were significant (P < 0.0001) for all tofacitinib treatment groups: 1 mg twice a day, 64.3%; 3 mg twice a day, 77.8%; 5 mg twice a day, 96.3%; and 10 mg twice a day, 80.8% versus placebo, 14.3%. A significant dose‐response relationship for the ACR20 was observed (P < 0.0001). Low disease activity was achieved by 72.7% of patients with high baseline disease activity for tofacitinib 10 mg twice a day at week 12 (P < 0.0001). Significant improvements in the ACR50, ACR70, Health Assessment Questionnaire Disability Index, and Disease Activity Score 28‐3 (C‐reactive protein) were also reported. The most commonly reported adverse events (AEs) were nasopharyngitis (n = 13) and increased alanine aminotransferase (n = 12) and aspartate aminotransferase (n = 9) levels. These AEs were mild or moderate in severity. Serious AEs were reported by 5 patients. No deaths occurred. Conclusion: In Japanese patients with active RA with an inadequate response to MTX, tofacitinib in combination with MTX over 12 weeks was efficacious and had a manageable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Revised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Self-citationKeystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., Pazdur, J., Bae, S.-C., Palmer, W., Zrubek, J., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 541
Interleukin-6 as a key player in systemic inflammation and joint destruction
Fonseca, J. E., Santos, M. J., Canhão, H., & Choy, E. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.01.012 · Cited by 375
Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., & Kishimoto, T. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0125-1 · Cited by 334
Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Azuma, J., & Kishimoto, T. (2009) · Modern Rheumatology · doi:10.3109/s10165-008-0125-1 · Cited by 268
Cited by
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Metadata
- Authors
- Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S. H., & Tofacitinib Study Investigators
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2011-08
- Volume
- 63
- Issue
- 8
- Pages
- 1150-1158
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W2129948300
- Cited by
- 297
- References
- 19
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. https://app.cochat.ai/papers/10.1002/acr.20494
- The paper
- Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., Zwillich, S. H., & Tofacitinib Study Investigators. (2011). Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care & Research. https://doi.org/10.1002/acr.20494
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.